Buprenorphine and Naloxone: Pregnancy Safety Explored
Episode Overview
Buprenorphine Naloxone combination may be safer during pregnancy. Methamphetamine use is rising as fentanyl deaths decrease. SAMHSA elimination could impact public health services. Statistical adjustments are crucial for non-randomized studies. Neonatal outcomes are key considerations for opioid treatment.
"The greatest irony of all is people in recovery hating on other people in recovery with how they recover."
In this episode of Addiction Medicine Journal Club, hosts Dr. John Keenan and Dr. Sonya Del Tredici tackle the complex topic of buprenorphine and naloxone use during pregnancy. With a study from JAMA as their backdrop, they explore whether combining buprenorphine with naloxone is safe for pregnant women compared to buprenorphine alone. They dive into a substantial study that screened millions to analyse 9,537 pregnancies, offering insights into neonatal outcomes like congenital malformations and neonatal abstinence syndrome.
The duo also touch on broader addiction issues, such as the alarming rise in methamphetamine use as fentanyl deaths slow. As the hosts navigate the maze of statistics, they highlight the challenges in addiction treatment and the potential impact of dismantling public health infrastructure, drawing parallels to historical lessons learned in Gettysburg. While their conversation is rich with data, it’s also peppered with light-hearted banter about office climates and desk plants, making for an engaging listen.
If you're curious about how addiction treatment intersects with pregnancy, this episode is a treasure trove of information, with a dash of humour to keep things lively.